References
- Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: New insight into an old antibiotic. Clin Infect Dis off Publ Infect Dis Soc Am. 2009;48:1729–1731.
- Karli A, Paksu MS, Karadag A, et al. Colistin use in pediatric intensive care unit for severe nosocomial infections: Experience of an university hospital. Ann Clin Microbiol Antimicrob. 2013;12:32.
- Kift EV, Maartens G, Bamford C. Systematic review of the evidence for rational dosing of colistin. S Afr Med J. 2014;104:183–186.
- Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin. 2008;24:377–391.
- Skov RL, Monnet DL. Plasmid-mediated colistin resistance (mcr-1 gene): Three months later, the story unfolds. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2016;21:pii=30155.
- Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
- Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241–4249.
- Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–3436.
- Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis. 2014;46:678–685.
- Azad MAK, Akter J, Rogers KL, Nation RL, Velkov T, Li J. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother. 2015;59:2136–2143.
- Ghlissi Z, Hakim A, Mnif H, et al. Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Ren Fail. 2013;35:1130–1135.
- Liu Y, Dai C, Gao R, Li J. Ascorbic acid protects against colistin sulfate-induced neurotoxicity in PC12 cells. Toxicol Mech Methods. 2013;23:584–590.
- Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother. 2012;67:452–459.
- Dalfino L, Puntillo F, Ondok MJM, et al. Colistin-associated acute kidney injury in severely ill patients: A step toward a better renal care? A prospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61:1771–1777.
- Lin Y, Shi R, Wang X, Shen H-M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8:634–646.
- Domitrović R, Cvijanović O, Pugel EP, Zagorac GB, Mahmutefendić H, Škoda M. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology. 2013;310:115–123.
- Ozkan G, Ulusoy S, Orem A, et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother. 2013;57:3463–3469.
- Dai C, Li J, Tang S, Li J, Xiao X. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother. 2014;58:4075–4085.
- An G, Wang X, Morris ME. Flavonoids are inhibitors of human organic anion transporter 1 (OAT1)-mediated transport. Drug Metab Dispos Biol Fate Chem. 2014;42:1357–1366.
- Dai C, Tang S, Deng S, et al. Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway. Antimicrob Agents Chemother. 2015;59:579–585.
- Ozyilmaz E, Ebinc FA, Derici U, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2011;37:141–146.